Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients with Non-Hodgkin's Lymphoma.

Trial Profile

Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients with Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Aprepitant; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Chemotherapy-induced nausea and vomiting; Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 25 May 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 31 Mar 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011, as reported in the ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top